Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buvidal for chronic pain in patients with opioid dependence
ACTRN12622000511730Phase 2Withdrawn
- Sponsor
- South Eastern Sydney Local Health District
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAM2038 in opioid use disorder (OUD) and chronic pain, sponsored by South Eastern Sydney Local Health District. Primary endpoint: Pain severity and pain interference. Planned start Apr 2022; status: withdrawn.
02
Drugs
CAM2038
03
Conditions
opioid use disorder (OUD)chronic pain
Beyond the preview
Go deeper on ACTRN12622000511730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000511730.